In this episode of Brilliant Together, host Daniel Hansson (Global Marketing Director) and Michael Cronquist Christensen (Global Medical Director) dive into the fascinating Memory study, which explored the use of Brintellix as an open-label, flexible-dose, 12-week study on patients with Major Depressive Disorder (MDD) and early-stage dementia.   

Daniel and Michael explain the study design and the decision to include all-cause dementia in the study, aiming to extend the relevance of the results to a broader patient pool; revealing exciting findings into the improvements in many different areas showcased by Brintellix. The clinical significance of these findings is energising as there is a lack of clean evidence supporting antidepressant treatments in this population. 

Key Takeaways:  

[0:47] How the pivotal MEMORY study—a 12-week exploration of Brintellix's impact on patients with Major Depressive Disorder and early-stage dementia— is unveiling new hope for those yearning for improved treatment options. 

[4:01] An overview of the MEMORY study design.  

[8:57] The results and data from the MEMORY study and the relevancy. 

[10:25] The main takeaways of these exciting results and how Brintellix can be utilised confidently by clinicians within this patient group.